- Home
- OCX vs LITB Comparison
OCX vs LITB Comparison
Compare OCX & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- LITB
- Stock Information
- Founded
- OCX 2009
- LITB 2007
- Country
- OCX United States
- LITB Singapore
- Employees
- OCX N/A
- LITB N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LITB Catalog/Specialty Distribution
- Sector
- OCX Health Care
- LITB Consumer Discretionary
- Exchange
- OCX Nasdaq
- LITB Nasdaq
- Market Cap
- OCX 80.1M
- LITB N/A
- IPO Year
- OCX N/A
- LITB N/A
- Fundamental
- Price
- OCX $4.09
- LITB $0.99
- Analyst Decision
- OCX Buy
- LITB
- Analyst Count
- OCX 3
- LITB 0
- Target Price
- OCX $4.42
- LITB N/A
- AVG Volume (30 Days)
- OCX 117.8K
- LITB 20.4K
- Earning Date
- OCX 04-11-2025
- LITB 03-24-2025
- Dividend Yield
- OCX N/A
- LITB N/A
- EPS Growth
- OCX N/A
- LITB N/A
- EPS
- OCX N/A
- LITB N/A
- Revenue
- OCX $709,000.00
- LITB $333,093,000.00
- Revenue This Year
- OCX N/A
- LITB N/A
- Revenue Next Year
- OCX $106.34
- LITB N/A
- P/E Ratio
- OCX N/A
- LITB N/A
- Revenue Growth
- OCX N/A
- LITB N/A
- 52 Week Low
- OCX $1.92
- LITB $0.91
- 52 Week High
- OCX $4.75
- LITB $6.00
- Technical
- Relative Strength Index (RSI)
- OCX 82.77
- LITB 39.53
- Support Level
- OCX $3.60
- LITB $0.92
- Resistance Level
- OCX $3.95
- LITB $1.05
- Average True Range (ATR)
- OCX 0.41
- LITB 0.06
- MACD
- OCX 0.15
- LITB 0.01
- Stochastic Oscillator
- OCX 72.83
- LITB 26.92
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.